For patient 8, who experienced hidradenitis suppurativa (HS) while on treatment with ixekizumab, switching to secukinumab was a reasonable choice, as secukinumab, unlike ixekizumab has the approved therapeutic indication for this condition [25] considering the role of IL-17A in the pathogenesis of HS [5]. This evidence concerns the gene IL17A and histiocytic sarcoma.